| Nome |
# |
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-eb0b-7715-e053-1705fe0a6cc9
|
374
|
|
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries, file e1dcb338-4cfc-7715-e053-1705fe0a6cc9
|
164
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb32e-e0e1-7715-e053-1705fe0a6cc9
|
120
|
|
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice, file e1dcb334-9623-7715-e053-1705fe0a6cc9
|
117
|
|
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia., file e1dcb32e-d7a9-7715-e053-1705fe0a6cc9
|
94
|
|
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants, file e1dcb32e-cb30-7715-e053-1705fe0a6cc9
|
90
|
|
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart, file e1dcb334-97fb-7715-e053-1705fe0a6cc9
|
89
|
|
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients, file e1dcb335-fa56-7715-e053-1705fe0a6cc9
|
77
|
|
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment, file e1dcb334-e5ae-7715-e053-1705fe0a6cc9
|
70
|
|
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission, file e1dcb335-2d69-7715-e053-1705fe0a6cc9
|
69
|
|
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia, file e1dcb330-4aea-7715-e053-1705fe0a6cc9
|
67
|
|
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors, file e1dcb332-e6a2-7715-e053-1705fe0a6cc9
|
62
|
|
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients., file e1dcb32e-cf5e-7715-e053-1705fe0a6cc9
|
58
|
|
Frontline Dasatinib Treatment in a “Real-Life” Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia, file e1dcb335-7389-7715-e053-1705fe0a6cc9
|
51
|
|
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase, file a2ddbbae-3e3e-4827-ab0c-ba41e4f594b6
|
48
|
|
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study, file e1dcb337-8c52-7715-e053-1705fe0a6cc9
|
35
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb332-80d5-7715-e053-1705fe0a6cc9
|
21
|
|
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study, file eeff9c5c-e26a-4327-bc3d-1f397811c3a7
|
20
|
|
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors, file 8c4fbec8-d0ba-46ea-ac30-2cf21af6879a
|
19
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb332-80d1-7715-e053-1705fe0a6cc9
|
17
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb332-80d3-7715-e053-1705fe0a6cc9
|
17
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb332-80d4-7715-e053-1705fe0a6cc9
|
17
|
|
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia, file e1dcb332-80d6-7715-e053-1705fe0a6cc9
|
16
|
|
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants, file ec74162e-a1d7-41fa-be71-71b7753d43ea
|
13
|
|
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants, file d8432af2-940b-41dc-a927-a49f7f09d585
|
12
|
|
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia, file e1dcb335-14cf-7715-e053-1705fe0a6cc9
|
12
|
|
Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study, file 7660074f-2b6c-4b3c-bbe9-6c6eb4ad2747
|
11
|
|
Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance, file e1dcb32e-de65-7715-e053-1705fe0a6cc9
|
11
|
|
Current treatment approaches in CML., file facd034c-5d4b-4e46-9b04-3fea2a5d765b
|
11
|
|
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs), file e1dcb331-0af5-7715-e053-1705fe0a6cc9
|
10
|
|
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia, file 0b6db5c0-d440-485e-9f6b-321718215366
|
7
|
|
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR), file e1dcb330-ea71-7715-e053-1705fe0a6cc9
|
7
|
|
Hematology patient protection during the covid-19 pandemic in Italy: A nationwide nursing survey, file 587304e0-e2eb-4227-acfa-f2f19b9e3c3b
|
6
|
|
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study, file 5b5f72b2-5339-4c53-9af8-17aade66cdc0
|
6
|
|
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools, file 9fe27f4d-e8f6-4abd-a767-47aa49234fc3
|
6
|
|
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study, file c1380f92-fec3-4a23-ae61-d2ae037435e2
|
6
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-e3fc-7715-e053-1705fe0a6cc9
|
6
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-e3fd-7715-e053-1705fe0a6cc9
|
6
|
|
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia, file 829381a9-b2ae-41f5-9346-0d2421cb4983
|
5
|
|
Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia, file 46f7ceb2-ea8e-45d2-9c5e-25547f3c1572
|
4
|
|
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study, file 90453892-ecd7-4dce-9c53-c671f76120c9
|
4
|
|
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy, file e1dcb330-c14f-7715-e053-1705fe0a6cc9
|
4
|
|
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study, file e1dcb330-fdbf-7715-e053-1705fe0a6cc9
|
4
|
|
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP, file e1dcb333-f43f-7715-e053-1705fe0a6cc9
|
4
|
|
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights, file 902efd85-6eb6-494c-b53b-132bf388035b
|
3
|
|
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients, file e1dcb32e-e051-7715-e053-1705fe0a6cc9
|
3
|
|
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia, file e1dcb330-3cf4-7715-e053-1705fe0a6cc9
|
3
|
|
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation, file 3eb19e4d-0e11-47a4-83fd-b5ddf8df7282
|
2
|
|
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network, file 5828df37-d362-4cb1-9570-094065a30847
|
2
|
|
Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies, file 69ce8011-97d3-46a7-8b1d-f9463e7ba5e1
|
2
|
|
Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study, file 8598d75d-99eb-45c1-b2a2-825a96464ee6
|
2
|
|
Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia, file cb50630a-b6a6-4e13-b4ce-ea98f680e66f
|
2
|
|
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia, file dbb40281-cb7f-4a69-992f-c9bbaa909228
|
2
|
|
null, file e1dcb337-ff08-7715-e053-1705fe0a6cc9
|
2
|
|
Italian Physicians’ Perceptions about the Role of Asciminib in Later Lines Chronic Myeloid Leukemia in Clinical Practice: A GIMEMA Survey, file 9c4fb5d3-3b87-4bb6-a7db-c25c47ee51ae
|
1
|
|
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials, file c37a716d-beb9-4a24-a78d-f14cd5a0232c
|
1
|
|
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib, file e1dcb32e-d80b-7715-e053-1705fe0a6cc9
|
1
|
|
null, file e1dcb32e-ddc7-7715-e053-1705fe0a6cc9
|
1
|
|
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia, file e1dcb330-7faf-7715-e053-1705fe0a6cc9
|
1
|
|
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview, file e1dcb337-eb0e-7715-e053-1705fe0a6cc9
|
1
|
| Totale |
1.896 |